TW202417044A - 抗ｃｄ２０抗體之醫藥組成物及其用途 - Google Patents

抗ｃｄ２０抗體之醫藥組成物及其用途 Download PDF

Info

Publication number
TW202417044A
TW202417044A TW112127368A TW112127368A TW202417044A TW 202417044 A TW202417044 A TW 202417044A TW 112127368 A TW112127368 A TW 112127368A TW 112127368 A TW112127368 A TW 112127368A TW 202417044 A TW202417044 A TW 202417044A
Authority
TW
Taiwan
Prior art keywords
antibody
compositions
pharmaceutical composition
disorder
mediated disease
Prior art date
Application number
TW112127368A
Other languages
English (en)
Inventor
亞歷山大 伊科列夫
葉卡琳娜 洛姆科娃
亞歷姍卓 索佐諾瓦
阿里納 津金納奧里翰
達利亞 波森
狄密崔 摩羅佐
Original Assignee
***聯邦商拜奧卡德聯合股份公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ***聯邦商拜奧卡德聯合股份公司 filed Critical ***聯邦商拜奧卡德聯合股份公司
Publication of TW202417044A publication Critical patent/TW202417044A/zh

Links

Abstract

本發明涉及藥學和醫學領域，尤其是涉及抗CD20抗體之醫藥組成物，所述抗CD20抗體特別是divozilimab，所述組成物可以用於治療CD20介導的疾病或病症。本發明進一步涉及所述組成物用於治療CD20介導的疾病或病症的用途，以及治療CD20介導的疾病或病症的方法，包括施用所述組成物。
TW112127368A 2022-07-26 2023-07-21 抗ｃｄ２０抗體之醫藥組成物及其用途 TW202417044A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RURU2022120466 2022-07-26
RURU2022127768 2022-10-26

Publications (1)

Publication Number Publication Date
TW202417044A true TW202417044A (zh) 2024-05-01

Family

ID=

Similar Documents

Publication Publication Date Title
WO2008050329A3 (en) Novel sirnas and methods of use thereof
FR2949044B1 (fr) Composition comprenant une fraction d'insaponifiable
MX2019012884A (es) Terapia de combinacion.
WO2007100675A3 (en) Collagenase for treating cellulite
ATE322265T1 (de) Pharmazeutische zusammensetzung zur behandlung von kolorektalem krebs welche thalidomid und irinotecan enthält
WO2006098603A3 (en) Composition comprising isoorientin for suppressing histamine
WO2021239935A9 (en) Neutralizing antibodies against sars-related coronavirus
TW200628473A (en) Novel heterocycles
EP4279128A3 (en) Novel antibody binding to tfpi and composition comprising the same
WO2004103297A3 (en) Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis
BRPI0507482A (pt) combinação de (a) um inibidor de dna topoisomerase e (b) um inibidor de iap
MX2019003173A (es) Terapia de combinacion con agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada.
BR112022018645A2 (pt) Composições e métodos para tratar ou prevenir doenças inflamatórias, incluindo diabetes mellitus tipo i e tipo ii e doenças da tireoide
WO2007056301A3 (en) Antibody therapy for treatment of diseases associated with gluten intolerance
MX2012001708A (es) Anticuerpo humanizado anti-oligomero de amiloide b.
WO2022192594A3 (en) Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease
BRPI0409796A (pt) uso de dipiridamol ou mopidamol para tratamento e prevenção de doenças tromboembolìticas e distúrbios provocados pela formação excessiva de trombina e/ou pela expressão elevada de receptores de trombina
BR112023021131A2 (pt) Tratamento de tremor essencial
WO2022079290A3 (en) Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
AU2021339851A8 (en) Method of treating amyloidosis
EA201992178A1 (ru) Фармацевтические композиции с высоким содержанием лекарственного средства из среднецепочечных триглицеридов и способы, связанные c ними
WO2007100590A3 (en) Methods for treating cellulite
WO2006029487A8 (en) Platelet factor 4 variant 1 (pf4var1) related inhibitors of angiogenesis
TW202417044A (zh) 抗ｃｄ２０抗體之醫藥組成物及其用途
ATE502637T1 (de) Medikamente zur prävention oder behandlung von herzversagen mit einem anticholinergikum